All News

purpura

Livedo, Purpura and Coagulopathy in Severe COVID-19

Jack Cush, MD

JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.

Read Article
CDC.jpg (keep)

CDC Reverses Guidance for Asymptomatic COVID Contacts

Jack Cush, MD

Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.

Read Article
podcast logo

RheumNow Podcast – Lupus Delights (9.18.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
COVID infection mask

COVID-19 Risks in Pregnant Women

Jack Cush, MD

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

Read Article
podcast logo

RheumNow Podcast – To Celiac Test or Not? (9.4.20)

Jack Cush, MD

Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:

Read Article
heart-665185__180.jpg

COVID and the Multisystem Inflammatory Syndrome in Children

Jack Cush, MD

Lancet Infectious Disease has reviewed the epidemiology, causes, clinical features, and current treatment for the multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19, noting severe organ damage can occur pediatric COVID-19 patients who are severely ill.&

Read Article
CDC.jpg (keep)

CDC: COVID Seroprevalence in Health Care Workers

MMWR

CDC reports that gmong 3,248 healthcare personnel (HCP) observed, 6% had antibody evidence of previous SARS-CoV-2 infection; 29% of personnel with SARS-CoV-2 antibodies were asymptomatic in the preceding months, and 69% had not previously received a diagnosis of SARS-CoV-2 infection.

Read Article
As of 20 Sept, CDC reports total US COVID-19 deaths to be 198,754. In the last 7 days 281,490 new Cases. Trends flat averaging ~40,000 Cases per day and ~600-1100 deaths per day. https://t.co/CPLVhz6qeH

Links:

Dr. John Cush RheumNow ( View Tweet)

Thank you all who participated in the survey. Here are some of our results #Covid_19 #rheumatology https://t.co/55ETf6kK6T

Links:

Bella Mehta bella_mehta ( View Tweet)

The RheumNow podcast is up! Lupus delights - Lupus & Diet, Drug induced lupus & brand new biologics for SLE. Good news on immunosuppressives, colchicine and baricitinib in COVID-19 patients. . Watch it here https://t.co/Ymsd3eXN5d or listen to the podcast https://t.co/20FOr3qu3X

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective cohort study of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater risk of hospitalized or ventilation and immunosuppressive use was not shown to worsened the course of disease (TNFi decreased risk of hospitalization) https://t.co/gmIXDJkLCt

Links:

Dr. John Cush RheumNow ( View Tweet)

Baricitinib in combo with Remdesivir reduces time to recovery in COVID-19 hospitalized pts in NIH-run ACTT-2 Trial w/ >1000 pts randomized to recv 4-mg baricitinib plus remdesivir versus remdesivir alone. Other baricitinib-COVID trials are in progress https://t.co/J87Ypeb4mn

Links:

Dr. John Cush RheumNow ( View Tweet)

Proof-of-concept study colchicine use in the context of COVID-19 infection leads to better survival. 140 consecutive COVID inpatients were Rx w/ standard of care +/- Colchicine. Survival rate @21d was better w/ colchicine (84% vs 64%;p=0.001). https://t.co/OzYd7pZ2ys

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish matched (1:4) cohort study shows COVID-19 pts taking NSAIDs had no greater risk of mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy; study included 9,236 COVID PCR-positive & 2.7% were on NSAIDs https://t.co/OuUbJ9FxiM

Links:

Dr. John Cush RheumNow ( View Tweet)

Cell phone use and location data during the COVID pandemic shows greater reductions in cell phone activity in the workplace and retail locations, and greater increases in activity at the residence, are associated with lesser growth in COVID-19 cases. https://t.co/3tRAbqqy4i

Links:

Dr. John Cush RheumNow ( View Tweet)

Another metanalysis of Chloroquine, HCQ, or azithromycin in COVID-19 shows HCQ not associated w/ reduced mortality (RR=0.83; 0.65-1.06) in hospitalized COVID-19, but combo of HCQ & azithromycin significantly increased mortality (RR=1.27; 1.04-1.54) https://t.co/xGEGyywxBJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Sanofi suspended Kevzara (sarilumab; 200 or 400 mg) studies in severe hospitalized COVID-19 infx - phase 3 trials didnt meet primary or secondary endpoints vs PBO. 420-Pt multinational trial had similar SAE and death rates in all 3 arms https://t.co/YkuKnVm9B8

Links:

Dr. John Cush RheumNow ( View Tweet)

President Trump took HCQ/Azithromycin.... Lancet Rheumatology reports that HCQ in RA has no cardiac risk but long term HCQ increases risk cardiovascular mortality, that may be further augmented by azithromycin. https://t.co/JRtkkAuEeu

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Rheum Lives Matter. More about social change, HCQ, JAKs & skin, growing cartilage, FM exercise. Watch it here>https://t.co/LLvADsDJ5O or listen to the Podcast here>https://t.co/pCXzaJUS9s

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - The Bad News That's Fit to Print (8.21.20) Dr Jack Cush reviews this week highlights filgotinib rejection, delays in Diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX https://t.co/1oZtU14VOB https://t.co/rcWlbYVKYn

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×